X

Trial Profile

LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Encorafenib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms BIRMA; GMMG-BIRMA

Most Recent Events

22 Nov 2023 Status changed from discontinued to completed.
28 Apr 2023 Status changed from active, no longer recruiting to discontinued.
06 Jan 2023 Results assessing efficacy and safety of combined BRAF/MEK inhibition, using encorafenib and binimetinib, in patients with relapsed/refractory multiple myeloma carrying a BRAFV600E mutation published in the Blood

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com